Goal 2: Reduce Human Disease

Best antibiotic regimen to treat community-acquired pneumonia

Community-acquired pneumonia (CAP) is responsible for over 1 million hospital admissions and about 100,000 deaths per year. We still do not know the best antibiotic regimen to treat CAP. Retrospective studies and cohort studies support giving macrolides, while randomized controlled studies (essentially all done by pharma) have not shown benefit of macrolides.  Guidelines allow either a macrolide or a quinolone.

Tags (Keywords associated with the idea)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Critical Challenge (CC)

Details on the impact of addressing this CQ or CC :

This is an area that needs to be studied, because if the macrolides provide the benefit suggested by many studies (about 20% mortality benefit), much morbidity and mortality would be prevented by universal macrolide use for CAP.  I am not aware of any studies being performed that would answer this question.

Name of idea submitter and other team members who worked on this idea : American Thoracic Society member


1 net vote
1 up votes
0 down votes
Idea No. 1624